Delegates who would like to present their work at the meeting, either orally or as a poster, are invited to submit an abstract for consideration by the Scientific Committee.
Abstracts sent by post or email will not be accepted. No exceptions will be made.
The content of the abstract must be related to one of the topics listed below. To ensure smooth scoring of papers, the topic of your work must be selected during the submission process.
1. Acquired coagulation disorders/inhibitors
4. Animal models
5. Antiphospholipid syndrome
6. Antiplatelet agents
7. Arterial vascular disorders
9. Blood coagulation tests
10. Cancer and thrombosis/hemostasis
11. Clinical prediction rules
12. Factor VIII – Factor IX
13. Coagulation factor V, X, II, XIII
14. Contact system
15. Disseminated intravascular coagulation
16. Endothelium/vessel wall
18. Fibrinolytic system
19. Guidance and guidelines
20. Hemophilia – clinical
21. Heparin and heparinoids
22. Heparin-induced thrombocytopenia (HIT)
23. Immune thrombocytopenia (ITP)
25. Innate and acquired immunity
26. Intravascular devices and intervention
27. Management of bleeding
28. Massive blood loss
29. Megakaryocytes and thrombopoiesis
31. Myocardial infarction
32. Natural anticoagulants
33. Non-vitamin K antagonist oral anticoagulants
34. Nurses and Allied Health
35. Pediatric thrombosis and hemostasis
36. Platelet activation/adhesion/aggregation
37. Platelet disorders, inherited/acquired
38. Platelet transfusion
39. Platelets and cancer
40. Post-thrombotic syndrome
41. Rare bleeding disorders
42. Regulation of coagulation and fibrinolysis
43. Reproductive issues
44. Risk factors venous thrombosis
45. Regulation of gene expression in vascular cells
46. Signal transduction
49. Tissue factor – Factor VII
51. TTP/thrombotic microangiopathies
52. Vascular progenitor and stem cells
53. Venous thromboembolism – diagnosis
54. Venous thromboembolism – epidemiology
55. Venous thromboembolism - therapy
56. Vitamin K antagonists
57. Von Willebrand disease
58. Von Willebrand Factor
Late breaking clinical trials abstracts
Clinical trials, the results of which will be available after the abstract submission deadline, can be submitted as such on a regular abstract including title and methods, and mentioning that results will be submitted as soon as available, and presented at the meeting. The abstract should be submitted under the type selection "ISTH 2015 Late Breaking Clinical Trial". Depending upon the date of submission of the results, they may be included in the Abstracts CD Rom or on the website only. If the results obtained in the Late Breaking Clinical Trial are not submitted to the Congress Office by May 19, 2015 the corresponding abstract will be withdrawn. Please note that a preliminary abstract needs to be submitted by the February 4, 2015 deadline to be considered.
o Conclusion (or Conclusions)
o Keywords: please choose four keywords.
o Registration of co-authors: please fill out the family names, first names, institute, city, country and e-mail addresses of the co-authors.
o Graphs, tables and pictures are not allowed
o Do not include a table in the body text of your abstract
o Conflict of interest: It is the intent of the ISTH to provide high-quality sessions focused on educational content that is free from commercial influence or bias. Thus the submitting author of an abstract is requested to declare any potential conflicts of interest for all authors during abstract submission.
Language setting of your keyboard
The keyboard configuration of computers in non-Western countries may cause problems with the printing of the abstracts when special non-Western characters are used. To avoid these problems the language setting of your computer should be changed. To do this select "Start" then Settings", then "Control Panel" and then choosing "Keyboard."
Once in this menu, set the language of your computer to English (United States) or US (International). Next, open MS Word (or the word processing software you are using) and set the font type to Arial. In the preparation of your abstract, if you require certain special characters that are not available, (e.g. '±', '®', 'μ'), use the insert symbol feature (special characters). To do this, select Arial as the font (unicoded, if possible), then select the required character, and copy and paste the symbol into the text of the abstract. If a special character is still not available, describe the character, e.g. 'alpha’.
Browser font preference: Before submitting your abstract, select Unicode as the preferred font. If Unicode is not available, please select Western.
Young Investigator Award
The Young Investigators Awards are provided in the form of travel grants to medical trainees and young scientists and are intended to assist with expenses relating to their participation at the Congress. Travel grants, consisting of CAD 700 will be available only for investigators who are first author on an accepted abstract. Travel grants are specifically intended to support young investigators; therefore applicants should be younger than 35 of age as of June 25, 2015. The Scientific Committee will decide, according to the scores of the abstracts, which investigator receives a travel grant. This will be announced to the first author by e-mail before April 30, 2015.
Authors wishing to be considered for a grant should be:
· the first author of a submitted abstract
· 35 years or younger of age (for 2015: authors born after June 25, 1980)
How to apply for a Young Investigator Award
· Tick the appropriate box at the online abstract submission site.
· Fill in the relevant questionnaire
· Only complete applications will be considered.
· The deadline for travel grant applications, supporting documents and additional information is February 4, 2015
To be eligible for the award, the recipient must attend the Meeting, and members of the ISTH will be given priority.
Reach the World Award
The International Society on Thrombosis and Haemostasis will award travel grants to clinicians and scientists from developing countries to help subsidize travel to the Congress (a copy of current passport showing country of residence will be required). Those that are presenter and first author of an abstract submitted to the Congress will be prioritized.
Please check the relevant box on the abstract submission form to indicate you wish to apply for this grant. For those not submitting abstracts, please apply to firstname.lastname@example.org and explain how this grant and congress will be of benefit in driving up standards of care for patients. To be eligible for the award, the recipient must attend the Congress.
Abstract review, selection and publication
· An international panel of experts will review the abstracts.
· Each abstract will be reviewed by 4-6 different experts.
· Abstracts may be selected for
o oral presentation
o poster presentation
· The first author will receive confirmation of acceptance for oral presentation, electronic poster presentation, or a notice of rejection, by April 22 via e-mail.
· No revisions can be made after the abstract deadline.
· There will be room for a very limited number of late breaking abstracts with a later deadline. The author still needs to submit a preliminary abstract by February 4 with sufficient information for the reviewers to understand the importance of the data. The author is required to select the Submission Type LATE BREAKING CLINICAL TRIAL. A final abstract has to be submitted to the Congress Secretariat by May 19, 2015.
· The best scoring abstracts will be selected for oral presentation.
· Authors of abstracts selected for oral presentation will be informed about the type and date of the session, and presentation guidelines will be provided.
· Poster presenters will be informed about the date of the poster exhibition and will receive guidelines for their preparation and presentation.
· All accepted abstracts will be published as addendum supplement to the Journal of Thrombosis and Haemostasis and will be made available on the congress website at the time of the meeting, and on a USB stick.
If authors wish to withdraw their abstracts from presentation or publication they are requested to send a letter via e-mail to the Congress secretariat before April 1, 2015.
Withdrawn abstracts cannot be presented nor will these be published.
Procedure abstract review & selection
All abstracts submitted by February 4 will be reviewed by an international panel of experts (representing all subspecialties from a large number of countries). The authors assign their abstracts to one of 58 topics. Within 10 days after the closure of the abstract submission, the reviewers (a total of about 500 experts) are requested to read and score each abstract in their category based on scientific merit. The scoring system is a scale ranging from 1 to 10, with a qualitative explanation of each grade. Once all abstracts have been reviewed, the scores are normalized and averaged.
The highest scoring abstracts are considered in detail and the top abstracts are selected for oral presentations.